Bravinton

General characteristics. Structure:

Active ingredient: 0,005 g of a Vinpocetine in 1 tablet.

Excipients, aerosil, magnesium stearate, potato starch, talc, lactose.

Pharmacological properties:

Pharmacodynamics. Drug Bravinton selectively improves a blood stream of a brain and portability of cerebral ischemia. The mechanism is caused by direct spasmolytic myotropic action on brain vessels. Strengthens a regional blood stream in an ishemizovanny zone of a brain, causes insignificant lowering of arterial pressure.

The Vinpocetine improves microcirculation in brain tissues, slows down aggregation of thrombocytes, reduces viscosity of blood. Increases resistance of cells of a brain to a hypoxia, strengthens aerobic process of utilization of glucose. Stimulates also anaerobic metabolism of glucose by braking of phosphodiesterase and stimulation of adenylatecyclase that leads to accumulation in cells of a brain of cycling AMF. Raises contents of catecholamines in a brain.

Pharmacokinetics. At internal reception it is quickly and completely absorbed in digestive tract. Bioavailability - 50 - 70%. The maximum concentration in plasma is reached in 1 hour. Therapeutic concentration in a blood plasma makes 10 - 20 ng/ml. An elimination half-life - 4,8 hour.

Indications to use:

Mental and neurologic symptoms of disturbances of cerebral circulation of a different origin (after a stroke, a craniocereberal injury, at an ateroskleroza of vessels of a brain) such as memory disturbance, dizziness, headache, disturbances of the movement, etc.

In ophthalmologic practice: at vascular diseases of mesh and vascular covers of an eye, at the degenerative changes of a macula lutea caused by atherosclerosis or a vasomotor spasm; at secondary glaucoma.

In otolaryngology: at senile relative deafness, Menyer's disease, at decrease in hearing vascular or toxic (including medicamentous) genesis, a sonitus, dizziness of a labyrinth origin.

Route of administration and doses:

Accept inside 5 - 10 mg 3 times a day.

Maintenance dose - 5 mg 3 times for days. Apply it is long. Improvement of a state is observed ordinary in 1-2 weeks; a course of treatment - not less than 2 months.

Features of use:

With care appoint Bravinton sick with severe forms of cardiac arrhythmias, the expressed coronary heart disease.

It is necessary to be careful during the work with mechanisms.

Side effects:

Perhaps insignificant lowering of arterial pressure, tachycardia, seldom premature ventricular contraction.

Interaction with other medicines:

There are no data about any clinically powerful medicinal interactions of Bravinton.

Contraindications:

Pregnancy, lactation, hypersensitivity to drug.

Overdose:

Till today cases of overdose by Bravinton were not registered. In case of developing of intoxication the symptomatic treatment is recommended.

Storage conditions:

To store in dry, protected from light and the place, unavailable to children, at the room temperature. A period of storage - 2 years. Not to apply after the term specified on packaging.

Issue conditions:

According to the recipe

Packaging:

In a blister strip packaging of 10 pieces, in a cardboard pack 2 packagings or in plastic bottles on 50 pieces, in a cardboard pack 1 bottle.